Eli Lilly (LLY) has surged ahead of Novo Nordisk (NVO) in the race for dominance in the anti-obesity market, recently reaching a $1 trillion market cap while Novo faces challenges. The shift in fortunes can be attributed to Eli Lilly’s successful launch of Zepbound, which outperformed Novo’s Wegovy in clinical trials, achieving an average weight loss of 20.2% compared to Wegovy’s 13.7%. Additionally, Zepbound’s approval for treating obstructive sleep apnea in overweight patients further solidifies Eli Lilly’s leading position.

The implications for financial markets are significant. Eli Lilly’s robust pipeline, including promising candidates like retatrutide, positions it for continued growth, while Novo Nordisk’s recent setbacks, including disappointing phase 3 results for its next-gen drug, have raised concerns about its competitive edge. Despite this, Novo’s lower valuation at 11.2x forward earnings compared to Eli Lilly’s 17.2x may present a buying opportunity for investors willing to bet on its potential recovery.

In summary, while Eli Lilly currently leads in the anti-obesity space, Novo Nordisk’s valuation and pipeline could attract investors looking for long-term gains, making both stocks worth monitoring as the market evolves.

Source: fool.com